ClinicalTrials.gg
RecruitingNCT07653100Updated Sep 24, 2026

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

A Phase 3 interventional study of RSVpreF and Placebo in Respiratory Syncytial Virus (RSV), sponsored by Pfizer. Recruiting at 13 sites in India. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)

Keywords

  • RSV, Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Participants ≥18 years of age at Visit 1.
  • Participants who are ambulatory and live independently in the community.
  • Participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Applicable to participants 18 through 59 years of age: Participants who are healthy or have stable preexisting diseases. These participants are considered at high risk of RSV disease by having at least 1 reportable stable chronic medical condition(s) that belongs to 1 or more of the following:
  • Chronic heart disease (ie, coronary artery disease, heart failure, or congenital heart disease)
  • Chronic lung disease (ie, , emphysema, asthma, interstitial lung disease, or cystic fibrosis)
  • Nongestational diabetes mellitus type 1 or type 2
  • Severe obesity ( [BMI] ≥40 kg/m2)
  • Chronic liver disease (ie, cirrhosis)
  • Chronic kidney disease (not including end-stage renal disease with or without dialysis)
  • Chronic neurological disease that causes impaired airway clearance or respiratory muscle weakness (ie, poststroke dysphagia, amyotrophic lateral sclerosis, or muscular dystrophy)
  • Chronic hematologic disease (ie, sickle cell disease or thalassemia)

Note: A chronic medical condition for this study is defined as:

  • Duration ≥6 months.
  • Requires regular medical follow-up or ongoing prescribed medication or hospitalization in the previous year.
  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol.

Key Exclusion Criteria:

  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
  • Prior history of any subtype of Guillain-Barré syndrome of any etiology.
  • Serious chronic disorder, including , end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
  • individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic , or radiotherapy, eg, for cancer or an disease, from 60 days before study intervention administration or planned receipt throughout the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    RSVpreF

    RSVpreF Vaccine

    Biological: RSVpreF

  • Placebo comparator
    Placebo

    Placebo

    Biological: Placebo

Interventions

  • BiologicalRSVpreF

    RSVpreF Vaccine

  • BiologicalPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of participants reporting local reactions within 7 days following investigational product administration

    Describe local reactions following investigational product administration

    Time frame: Within 7 days

  2. Percentage of participants reporting systemic events within 7 days following investigational product administration

    Describe systemic events following investigational product administration

    Time frame: Within 7 days

  3. Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration

    Describe AEs occurring through 1 month following administration of investigational product

    Time frame: 1 month after vaccination

  4. Percentage of participants reporting serious adverse events (SAEs) throughout the study

    Describe SAEs through 3 months following administration of investigational product

    Time frame: 3 months after vaccination

  5. Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titers (GMT)

    Time frame: Before vaccination, 1 month after vaccination

  6. NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)

    Time frame: Before vaccination, 1 month after vaccination

  7. NTs for RSV A and RSV B expressed as seroresponse rate

    Time frame: 1 month after vaccination

07

Study locations

13 of 13 sites recruiting
  • King George Hospital
    Visakhapatnam, Andhra Pradesh 530002, India
    Recruiting
  • BGS Global Institute of Medical Sciences (BGSGIMS)
    Bangalore, Karnataka 560060, India
    Recruiting
  • Radhakrishna Multispeciality Hospital and IVF Center
    Bangalore, Karnataka 560085, India
    Recruiting
  • Belagavi Institute of Medical Sciences - Belagavi
    Belagavi, Karnataka 590001, India
    Recruiting
  • Suyog Hospital
    Nashik, Maharashtra 422003, India
    Recruiting
  • Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre
    Pune, Maharashtra 411043, India
    Recruiting
  • Aakash Healthcare Private Limited
    Dwarka, National Capital Territory of Delhi 110075, India
    Recruiting
  • All India Institute Of Medical Sciences
    New Delhi, National Capital Territory of Delhi 110029, India
    Recruiting
  • Sir Ganga Ram Hospital
    New Delhi, National Capital Territory of Delhi 110060, India
    Recruiting
  • Maharaja Agrasen Superspeciality Hospital
    Jaipur, Rajasthan 302039, India
    Recruiting
  • SRM Medical College Hospital and Research Centre - Kattankulathur
    Chengalpattu, Tamil Nadu 603203, India
    Recruiting
  • Chettinad Hospital and Research Institute
    Kelambākkam, Tamil Nadu 603103, India
    Recruiting
  • Institute of Post Graduate Medical Education & Research, SSKM Hospital
    Kolkata, West Bengal 700020, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jan 2027, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 17, 2026
StartActual
Jun 22, 2026
Primary completionEst.
Jan 25, 2027
CompletionEst.
Jan 25, 2027
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07653100
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jun 22, 2026
Primary completion
Jan 25, 2027 (estimated)
Completion
Jan 25, 2027 (estimated)
Last update
Sep 24, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrysvo

Start the discussion